...
首页> 外文期刊>Journal of Foot and Ankle Research >IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2?year follow-up study
【24h】

IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2?year follow-up study

机译:IL-17细胞因子在糖尿病性夏科关节炎患者骨愈合中的作用:一项为期2年的前瞻性随访研究

获取原文

摘要

Background Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation of proinflammatory cytokines leading to increased osteoclastogenic activity and progressive bone destruction. Several members of the IL-17 family of proinflammatory cytokines have been shown to play a key role in the pathogenesis of inflammatory conditions affecting bone and joints but none has previously been studied in Charcot foot patients. The aim of this study was to investigate the role of IL-17A, IL-17E and IL-17F in patients presenting with Charcot foot. Methods Twenty-six consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI and circulating levels of IL-17A, IL-17E and IL-17F. Analysis of cytokines was done by ultra-sensitive chemiluminescence technique and data were analyzed by one-way repeated measures ANOVA. Neuropathic diabetic patients (n?=?20) and healthy subjects (n?=?20) served as controls. Results Plasma IL-17A and IL-17E in weight-bearing Charcot patients at diagnosis were at the level of diabetic controls, whereas IL-17F was significantly lower than diabetic controls. A significant increase in IL-17A and IL-17E reaching a peak 2–4 months after inclusion and start of offloading treatment in Charcot patients was followed by a gradual decrease to the level of diabetic controls at 2 years postinclusion. In contrast, IL-17F increased gradually from inclusion to a level not significantly different from diabetic controls after 2 years. Conclusions Charcot patients display a significant elevation of all three IL-17 cytokines during the follow-up period relative values at diagnosis and values in control patients supporting a role in the bone repair and remodeling activity during the recovery phase. The rapid increase of IL-17A and IL-17E shortly after initiating off-loading treatment could suggest this to be a response to immobilization and stabilization of the diseased foot.
机译:背景技术尽管引发创伤性促炎细胞因子可导致破骨细胞生成活性增加和进行性骨破坏,但脚部创伤已被认为是主要的启动因素,目前尚不清楚触发Charcot关节炎并调节其恢复的病理生理机制。已显示IL-17促炎细胞因子家族的几个成员在影响骨骼和关节的炎性疾病的发病机理中起关键作用,但以前从未在Charcot足部患者中进行过研究。这项研究的目的是调查IL-17A,IL-17E和IL-17F在炭黑足病患者中的作用。方法对2例连续的Charcot患者在2年内进行重复的足部X线摄影,MRI和IL-17A,IL-17E和IL-17F的循环水平监测。细胞因子的分析通过超灵敏化学发光技术进行,数据通过单向重复测量ANOVA进行分析。神经性糖尿病患者(n≥20)和健康受试者(n≥20)作为对照。结果确诊的负重Charcot患者的血浆IL-17A和IL-17E处于糖尿病对照水平,而IL-17F显着低于糖尿病对照。在Charcot患者入选并开始减负荷治疗后,IL-17A和IL-17E显着增加,达到峰值后2-4个月,随后在入选后2年逐渐降低至糖尿病对照水平。相反,IL-17F从包合逐渐增加到2年后与糖尿病对照组无明显差异的水平。结论Charcot患者在随访期间在诊断时的相对值和对照患者中显示的所有三种IL-17细胞因子均显着升高,而对照患者的值支持恢复阶段的骨修复和重塑活动。在开始减负荷治疗后不久,IL-17A和IL-17E的迅速增加可能表明这是对患病脚的固定和稳定的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号